Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some...
REDWOOD CITY, Calif., April 22, 2020 -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will.
Ladies and gentlemen, thank you for standing by and welcome to the Coherus BioSciences 2020 First Quarter Earnings Conference Call. This release can be found on the Coherus BioSciences website. Joining me for today's call will be Dennis M. Lanfear, Coherus' CEO, Dr. Jean-Frederic Viret, Chief Financial Officer, Thomas Fitzpatrick, Chief Legal Officer; and Chris Thompson, Executive Vice President, Sales & Market Access.
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Coherus also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional 30,000,000 principal amount of notes. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their notes at their option into shares of Coherus’ common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate.
Investors in Coherus BioSciences, Inc. (NASDAQ:CHRS) had a good week, as its shares rose 7.9% to close at US$17.30...
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA® and net income for the quarter ended March 31, 2020. Coherus also provided an update on the impact of COVID-19 for first quarter 2020 as well as additional insights on COVID-19 impact for the balance of 2020. The Company expects preliminary unaudited first quarter 2020 net product revenue to be between $115.0 million and $117.5 million, a 210% to 217% increase compared to the net product revenue of $37.1 million for the first quarter of 2019.
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
A Relative Strength Rating upgrade for Coherus Biosciences shows improving technical performance. Will it continue?
Many biotechs have been on hot streaks in 2020, particularly those with the coronavirus on their agenda, as valuations have shot up on the back of urgently needed solutions for COVID-19. But the trend hasn’t been industry wide, leaving out companies whose focus resides in other areas.Case in point: Coherus BioSciences (CHRS), a commercial-stage biopharma targeting the global biosimilar market. Despite periodic volatility, shares are down 9% in 2020. Looking back to 2019, though, the stock shot up by an impressive 102%. With shares currently trading 38% below the 52-week high, Maxim analyst Jason McCarthy argues CHRS is a “top pick for the COVID-19” environment.Coherus reported first quarter earnings last week, overall, delivering a positive report. Revenue came in at $116.2 million, although a little below the Street’s call for $119.4 million and down 6% 4Q19, yet still displaying a year-over-year increase of 213.2%. Non-GAAP EPS of $0.67 beat the estimates by $0.20.With $400 million of cash on the balance sheet, McCarthy argues the company’s financial health will see it through the uncertain COVID-19 environment and will most likely “fuel additional M&A activity.”Companies hurting from the pandemic’s impact and currently valued at discount prices, are ripe for the taking and should bode well for Coherus’ objective of adding another oncology asset in the near term. Additionally, Coherus’ pegfilgrastim biosimilar Udenyca is already the dominant player in its market, increasing its share from 20 to 20% through the quarter. With a bulging pipeline and several launches expected over the next few years, McCarthy is confident Coherus is set up well for further expansion.The 5-star analyst said, “With the economic uncertainty due to COVID-19, Coherus remains well-positioned with a strong balance sheet, and a fairly insulated market (oncology). We anticipate that Udencya should return to growth after a transient impact in 2Q20, and that M&A activity should help expand the Coherus pipeline, potentially coming with more favorable terms as less secure companies may face greater impact from economic conditions.”Accordingly, McCarthy has a Buy rating on CHRS shares to go along with a $27 price target. The implication for investors? Upside of 65% from current levels. (To watch McCarthy’s track record, click here)It appears the rest of the Street sees plenty of upside, too. Based on Buys only – 6, in fact – the analyst community rates Coherus a Strong Buy. The average price target hits $31, and implies potential upside of a healthy 89% over the coming months. (See Coherus stock analysis on TipRanks)Read more: * 3 Top Stock Picks From Wall Street’s 5-Star Analyst * Morgan Stanley: 2 Stocks That Could Surge Over 25% * 3 Stocks Millennials Are Betting Big on Right Now
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the pricing of the notes, Coherus entered into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates and/or other financial institutions (the “option counterparties”). If the initial purchasers exercise their option to purchase additional notes, Coherus expects to enter into additional capped call transactions with the option counterparties.
REDWOOD CITY, Calif., May 04, 2020 -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA.
– First Quarter UDENYCA® Net Sales of $116.2 Million ––Net Income of $35.6 Million –– Non-GAAP Net Income of $49.8 Million – REDWOOD CITY, Calif., May 07, 2020 -- Coherus.
Q1 2020 Coherus BioSciences Inc Earnings Call
These strong businesses could have high potential Continue reading...
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
S&P; Dow Jones Indices will make the following changes to the S&P; MidCap 400 and S&P; SmallCap 600 effective prior to the open of trading on Monday, June 1:
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.